Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Capricor Therapeutics, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][3]. Company Developments - On May 5, 2025, Capricor announced a mid-cycle review meeting with the FDA regarding its Biologics License Application for deramiocel, leading to a stock price drop of $3.00 per share (29.13%) to $7.30 on May 6, 2025 [3]. - Following a report on June 20, 2025, that the FDA canceled the advisory committee meeting for deramiocel due to concerns over the drug's efficacy and safety, Capricor's stock fell by $3.68 per share (30.82%) to close at $8.26 [3]. Legal Context - The law firm is encouraging investors who suffered losses from Capricor's stock to reach out for discussions regarding their legal rights and options [1][4].